首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent
Authors:Zhongpeng Ding  Hejuan Cheng  Shixiao Wang  Yingwei Hou  Jianchun Zhao  Huashi Guan  Wenbao Li
Institution:1. Key Laboratory of Marine Drugs of Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People’s Republic of China;2. Marine Biomedical Research Institute of Qingdao, Qingdao 266071, People’s Republic of China
Abstract:Plinabulin, a drug targeting microtubule of cancer cells, has been currently tried in its phase III clinical study. However, low efficacy caused by poor pharmacokinetic (PK) properties has been considered to be the main obstacle to approved by the Food and Drug Administration. Herein, we introduced a deuterium atom as an isostere in its structure to become a new compound named (MBRI-001, No. 9 in a series of deuterium-substituted compounds). The structure of MBRI-001 was characterized by HRMS, NMR, IR and a single crystal analysis. MBRI-001 exhibited better pharmacokinetic characteristics than that of plinabulin. Additionally, its antitumor activity is in a low nanomolar level for a variety of cancer cell lines and high activity against human NCI-H460 xenograted in mice intravenous administration. Importantly, continuous administration of MBRI-001 exhibited lower toxicity compared to docetaxel. We thus suggest that MBRI-001 could be developed as a promising anti-cancer agent in near future.
Keywords:ZWLWFCKNFSOIEA-UHFFFAOYSA-N  DKGPAJORZYZGOY-UHFFFAOYSA-N  FSTXHTKEZGSDNN-UHFFFAOYSA-N  DKGPAJORZYZGOY-APZFVMQVSA-N  FSTXHTKEZGSDNN-QYKNYGDISA-N  JMHLCUCEUQCHLL-QDRVQTHMSA-N  UNRCMCRRFYFGFX-JTSGUJNOSA-N  YVBVIJQMJDNVFD-UHFFFAOYSA-N  Plinabulin  Deuterium substituted  Microtubule  Pharmacokinetic properties  Docetaxel
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号